Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Zhonghai Du, Shuxian Niu, Juan Wang, Jun Wu, Sheng Li & Xiuxiu Yi. (2021) SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1/PD-L1 axis. Autoimmunity 54:4, pages 225-233.
Read now
Read now
Jan Trøst Jørgensen. (2021) An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. Expert Review of Molecular Diagnostics 21:5, pages 445-454.
Read now
Read now
Jan Trøst Jørgensen. (2020) Companion and complementary diagnostics: an important treatment decision tool in precision medicine. Expert Review of Molecular Diagnostics 20:6, pages 557-559.
Read now
Read now
Jan Trøst Jørgensen. (2020) Site-agnostic biomarker-guided oncology drug development. Expert Review of Molecular Diagnostics 20:6, pages 583-592.
Read now
Read now
Paul Hofman & Fabrice Barlesi. (2019) Companion diagnostic tests for treatment of lung cancer patients: what are the current and future challenges?. Expert Review of Molecular Diagnostics 19:5, pages 429-438.
Read now
Read now
Paul Hofman. (2017) PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?. Expert Review of Molecular Diagnostics 17:12, pages 1097-1108.
Read now
Read now
Chunwan Lu, Priscilla S. Redd, Jeffrey R. Lee, Natasha Savage & Kebin Liu. (2016) The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. OncoImmunology 5:12.
Read now
Read now
Articles from other publishers (37)
Katsunori Tanaka, Hitoshi Hirakawa, Mikio Suzuki, Teruyuki Higa, Shinya Agena, Narumi Hasegawa, Junko Kawakami, Masatomo Toyama, Tomoyo Higa, Hidetoshi Kinjyo, Norimoto Kise, Shunsuke Kondo, Hiroyuki Maeda & Taro Ikegami. (2023) Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer. Current Oncology 30:6, pages 5409-5424.
Crossref
Crossref
Minke W. Lucas, Judith M. Versluis, Elisa A. Rozeman & Christian U. Blank. (2023) Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. Nature Reviews Clinical Oncology 20:6, pages 408-422.
Crossref
Crossref
Suzanne Isabelle Sitnikova, Sophie Munnings-Tomes, Elena Galvani, Stacy Kentner, Kathy Mulgrew, Chris Rands, Judit España Agustí, Tianhui Zhang, Kristina M Ilieva, Guglielmo Rosignoli, Hormas Ghadially, Matthew J Robinson, Tim Slidel, Robert W Wilkinson & Simon J Dovedi. (2021) Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models. Journal for ImmunoTherapy of Cancer 9:6, pages e002894.
Crossref
Crossref
Julianne D. Twomey & Baolin Zhang. (2021) Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. The AAPS Journal 23:2.
Crossref
Crossref
Jan Trøst Jørgensen. 2021. Precision Medicine and Artificial Intelligence. Precision Medicine and Artificial Intelligence
97
107
.
Joe Yeong, Zitong Zhao, Jeffrey Chun Tatt Lim, Huihua Li, Aye Aye Thike, Valerie Cui Yun Koh, Bin Tean Teh, Ravindran Kanesvaran, Chee Keong Toh, Puay Hoon Tan & Li Yan Khor. (2020) PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas. Journal of Clinical Pathology 73:8, pages 463-469.
Crossref
Crossref
Raghavendra Pillappa & Adele O. Kraft. (2019) Immunohistochemical validation studies in effusion cytology: A cautionary tale. Cancer Cytopathology 127:11, pages 680-683.
Crossref
Crossref
Varani, Auletta, Signore & Galli. (2019) State of the Art of Natural Killer Cell Imaging: A Systematic Review. Cancers 11:7, pages 967.
Crossref
Crossref
Magdalena Zajac, Anne-Marie Boothman, Yong Ben, Ashok Gupta, Xiaoping Jin, Amita Mistry, Constantine Sabalos, Alma Nielsen, Guadalupe Manriquez, Craig Barker, Joyce Antal, Peiyi Wang, Pallavi Patil, Nicole Schechter, Marlon C. Rebelatto & Jill Walker. (2018) Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. Archives of Pathology & Laboratory Medicine 143:6, pages 722-731.
Crossref
Crossref
David B. Chapel, Rachel Stewart, Larissa V. Furtado, Aliya N. Husain, Thomas Krausz & Georgios Deftereos. (2019) Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Human Pathology 87, pages 11-17.
Crossref
Crossref
Benjamin Levy, Luis Paz-Ares, Jaafar Bennouna, Enriqueta Felip, Delvys Rodríguez Abreu, Dolores Isla, Fabrice Barlesi, Olivier Molinier, Jeannick Madelaine, Clarisse Audigier-Valette, Sang-We Kim, Hye Ryun Kim, Mustafa Ozguroglu, Mustafa Erman, Firas Benyamine Badin, Tarek M. Mekhail, Ronald Scheff, Michael J. Chisamore, Behbood Sadrolhefazi & Jonathan W. Riess. (2019) Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clinical Lung Cancer 20:3, pages e407-e412.
Crossref
Crossref
Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst & Simon F. Lacey. (2019) Engineered T Cell Therapies from a Drug Development Viewpoint. Engineering 5:1, pages 140-149.
Crossref
Crossref
Mei Gao, Miranda Lin, Richard A. Moffitt, Marcela A. Salazar, Jinha Park, Jeffrey Vacirca, Chuan Huang, Kenneth R. Shroyer, Minsig Choi, Georgios V. Georgakis, Aaron R. Sasson, Mark A. Talamini & Joseph Kim. (2018) Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. British Journal of Cancer 120:1, pages 88-96.
Crossref
Crossref
Verena Schildgen & Oliver Schildgen. 2019. Companion and Complementary Diagnostics. Companion and Complementary Diagnostics
413
427
.
Aaron R. Ellison & David A. Stanforth. 2019. Companion and Complementary Diagnostics. Companion and Complementary Diagnostics
243
263
.
Jan Trøst Jørgensen. 2019. Companion and Complementary Diagnostics. Companion and Complementary Diagnostics
11
25
.
Cory Batenchuk, Maher Albitar, Kim Zerba, Sucha Sudarsanam, Vladislav Chizhevsky, Chelsea Jin & Virginia Burns. (2018) A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies. Journal of Clinical Pathology 71:12, pages 1078-1083.
Crossref
Crossref
Yanchun Li, Mateusz Opyrchal, Song Yao, Xuan Peng, Li Yan, Hossam Jabbour & Thaer Khoury. (2018) The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. Breast Cancer Research and Treatment 170:2, pages 293-302.
Crossref
Crossref
Maria Hersom & Jan T. Jørgensen. (2018) Companion and Complementary Diagnostics–Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non–Small Cell Lung Cancer. Therapeutic Drug Monitoring 40:1, pages 9-16.
Crossref
Crossref
Kevin Washetine & Paul Hofman. (2018) L’immunohistochimie PD-L1 dans les cancers pulmonaires non à petites cellules, perspectives d’avenir. Revue Francophone des Laboratoires 2018:498, pages 39-48.
Crossref
Crossref
Mellar P. Davis & Rajiv Panikkar. (2018) Checkpoint Inhibitors, Palliative Care, or Hospice. Current Oncology Reports 20:1.
Crossref
Crossref
Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj & William K. Oh. (2017) Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. Journal for ImmunoTherapy of Cancer 5:1.
Crossref
Crossref
J. Hammerbacher & A. Snyder. (2017) Informatics for cancer immunotherapy. Annals of Oncology 28, pages xii56-xii73.
Crossref
Crossref
Gaurav Bajaj, Manish Gupta, Yan Feng, Paul Statkevich & Amit Roy. (2017) Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma. The Journal of Clinical Pharmacology 57:12, pages 1527-1533.
Crossref
Crossref
Mohammed S. I. Mansour, Tomas Seidal, Ulrich Mager, Amir Baigi, Katalin Dobra & Annika Dejmek. (2017) Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining. Cancer Cytopathology 125:12, pages 908-917.
Crossref
Crossref
Jason N. Rosenbaum & Paul Weisman. (2017) The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics. The American Journal of Pathology 187:10, pages 2185-2198.
Crossref
Crossref
Janice M. Mehnert, Arta M. Monjazeb, Johanna M.T. Beerthuijzen, Deborah Collyar, Larry Rubinstein & Lyndsay N. Harris. (2017) The Challenge for Development of Valuable Immuno-oncology Biomarkers. Clinical Cancer Research 23:17, pages 4970-4979.
Crossref
Crossref
Emina E. Torlakovic, Carol C. Cheung, Corrado D’Arrigo, Manfred Dietel, Glenn D. Francis, C. Blake Gilks, Jacqueline A. Hall, Jason L. Hornick, Merdol Ibrahim, Antonio Marchetti, Keith Miller, J. Han van Krieken, Soren Nielsen, Paul E. Swanson, Mogens Vyberg, Xiaoge Zhou & Clive R. Taylor. (2017) Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories. Applied Immunohistochemistry & Molecular Morphology 25:3, pages 151-159.
Crossref
Crossref
Carol C. Cheung, Corrado D’Arrigo, Manfred Dietel, Glenn D. Francis, C. Blake Gilks, Jacqueline A. Hall, Jason L. Hornick, Merdol Ibrahim, Antonio Marchetti, Keith Miller, J. Han van Krieken, Soren Nielsen, Paul E. Swanson, Clive R. Taylor, Mogens Vyberg, Xiaoge Zhou & Emina E. Torlakovic. (2017) Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers. Applied Immunohistochemistry & Molecular Morphology 25:1, pages 4-11.
Crossref
Crossref
J.T. Jørgensen & K.B. Nielsen. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
530
545
.
Marlon C. Rebelatto, Anita Midha, Amita Mistry, Constantine Sabalos, Nicole Schechter, Xia Li, Xiaoping Jin, Keith E. Steele, Paul B. Robbins, John A. Blake-Haskins & Jill Walker. (2016) Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagnostic Pathology 11:1.
Crossref
Crossref
Jan Trøst Jørgensen. (2016) Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives. Trends in Cancer 2:12, pages 706-712.
Crossref
Crossref
Ralph E. Parchment, Andrea Regier Voth, James H. Doroshow & Jay A. Berzofsky. (2016) Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. Seminars in Oncology 43:4, pages 501-513.
Crossref
Crossref
Kristen R. SpencerJianfeng WangAnn W. SilkShridar GanesanHoward L. KaufmanJanice M. Mehnert. (2016) Biomarkers for Immunotherapy: Current Developments and Challenges. American Society of Clinical Oncology Educational Book:36, pages e493-e503.
Crossref
Crossref
Marius Ilie, Véronique Hofman, Manfred Dietel, Jean-Charles Soria & Paul Hofman. (2016) Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Archiv 468:5, pages 511-525.
Crossref
Crossref
Aleksandra Mędra, Agata Majchrzak & Piotr Smolewski. (2016) Inhibitory immunologicznych punktów kontrolnych podziału komórki w leczeniu chorób nowotworowych. Acta Haematologica Polonica 47:2, pages 155-162.
Crossref
Crossref
Till Plönes, Walburga Engel-Riedel, Erich Stoelben, Christina Limmroth, Oliver Schildgen & Verena Schildgen. (2016) Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer. Journal of Personalized Medicine 6:1, pages 3.
Crossref
Crossref